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BACKGROUND: Tacrolimus (formerly FK 506) was first 
used clinically in 1989 to successfully replace cyclo-
sporine in hepatic transplant recipients who were ex-
periencing intractable rejection or as the baseline drug 
from the time of operation. After extensive pilot ex-
perience, an institutional review board-mandated clini-
cal trial comparing cyclosporine with tacrolimus was 
performed. 
STUDY DESIGN: From February 16, 1990 to December 
26, 1991, 154 patients were recruited. The competing 
drugs were combined with equal induction doses of 
prednisone in both arms of the study for the trrst 
81 patients and with subsequently higher doses of 
prednisone in the remaining 35 patients who received 
cyclosporine and were entered into the trial. Drug 
crossover was permitted for lack of efficacy or adverse 
events. End points were rejection confirmed by biopsy 
and treatment failure leading to retransplantation or 
death. 
RESULTS: Seventy-nine patients were randomized to 
the tacrolimus arm and 75 to the cyclosporine arm 
during 1990 and 1991. All patients were available for 
follow-up throughout the trial, which terminated on 
May 30, 1995. The mean duration of follow-up was 
four years. Patients randomized to the tacrolimus arm 
were less likely to experience acute rejection than 
were those receiving cyclosporine, with 36.2 percent 
of the patients receiving tacrolimus and 16.8 percent 
of the patients receiving cyclosporine showing freedom 
from rejection at one year (p=0.003, likelihood ratio 
test). Survival of patients over the course of the study 
was virtually the same in the two groups. 
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CONCLUSIONS: Tacrolimus was more effective than 
cyclosporine in preventing acute rejection. J. Am. COU. 
Surg., 1996, 183: 117-125. 
ALTHOUGH a properly designed and executed ran-
domized controlled trial (RCT) is the best way 
to determine the effectiveness of competing ther-
apies, such studies are underrepresented in the 
surgical literature (1, 2). A partial explanation 
has been provided by Solomon and McLeod (3), 
who found that even in an ideal clinical research 
setting, only 40 percent of questions involving 
a surgical procedure could have been answered 
by an RCT. Although Solmon and McLeod sup-
port RCTs whenever such studies are feasible, 
they stated that" ... if a new treatment is shown 
to result in a dramatic improvement in outcome 
in uncontrolled, immediate historic controlled 
trials or nonrandomized controlled trials, an RCT 
may be unnecessary or even unethical" (3). On 
the other hand, undue adherence to such lines 
of reasoning has hampered therapeutic progress 
by allowing inappropriate or ineffective therapy, 
or both, to become institutionalized on the basis 
of case series and retrospective studies. 
We report herein the long-term results from 
and dilemmas posed by an RCT that has been 
inundated by the foregoing controversies. The 
trial comparing the immunosuppressants tacro-
limus (FK 506, PrograCM , Fujisawa USA, Inc., 
Deerfield, IL) and cyclosporine (Sandimmune®, 
Sandoz Pharmaceuticals, East Hanover, NJ) for 
hepatic transplantation was required as a condi-
tion for continuing the clinical development of 
tacrolimus. However, the drug already had been 
shown to systematically rescue hepatic allografts 
from otherwise intractable rejection (4, 5) and 
to cause no unique or unexpected toxicity com-
pared with cyclosporine when used as long-term 
therapy (5, 6). In addition, improved survival of 
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patients and grafts with reduced dependence on 
adjuvant adrenal corticosteroids relative to his-
torical controls had been observed in almost 200 
recipients treated with tacrolimus from the time 
of hepatic or other organ transplantation (7-10). 
Two design features made the Pittsburgh RCT 
reported here conceptually different from the 
European (11) and American (12) multicenter 
trials that were started later. In this single-center 
trial, tacrolimus and cyclosporine were compared 
"head to head," with all other treatment factors 
(including corticosteroids) balanced at baseline 
(13). In addition, both competing drugs were 
used flexibly, with rapidly adjustable doses, rather 
than with the limited dose maneuverability that 
was a feature of the multicenter trials. Conse-
quently, problems with overdosing of tacrolimus 
and consequent side effects that were charac-
teristic of the subsequent multicenter trials on 
both sides of the Atlantic were avoided. 
MATERIALS AND METHODS 
Inclusion and exclusion criteria. All male and fe-
male patients aged 16 to 60 years referred to 
the University of Pittsburgh for hepatic trans-
plantation were considered to be potential can-
didates for randomization. Patients were excluded 
if they were hepatitis B virus carriers, had cancer, 
were undergoing transplantation of multiple or-
gans, had serum creatinine levels greater than 
2 mg percent, had active infection, were in stage 
4 coma (unconscious and ventilator dependent), 
had clinically significant heart or lung disease, 
or had had previous hepatic hilar reconstructive 
or portal venous bypass procedures. Pregnant or 
nursing women were also excluded. 
Details of randomization. Informed consent was 
obtained in advance for all patients, and patients 
were randomized four hours after full revascu-
larization. Treatment assignment (using sealed-
envelope implementation) was determined by a 
computer-programmed block randomization 
technique (block size of eight) to assure that 
the treatment groups remained reasonably bal-
anced. Randomization was aborted if the opera-
tion was technically unsatisfactory or if inadequate 
bile production or intraoperative biochemical 
blood studies (such as documentation of lactic 
acidosis) suggested substandard graft function. 
Once randomization was performed, continuous 
intravenous (IV) infusion of tacrolimus or cy-
closporine was started within two hours. The sur-
geons did not know the randomization status 
during the donor search at operation or in the 
early intraoperative phase. 
Determination of rejection of the hepatic transplant. 
Postoperative ultrasound studies of the hepatic 
vascular structure and bile ducts were routinely 
performed. When findings on ultrasound were 
equivocal, a cholangiogram and an arteriogram 
were performed. Protocol biopsies were obtained 
after approximately ten postoperative days, before 
discharge from the hospital, and at two months. 
Additional biopsies were obtained when indicated 
by clinical events. 
Clinical criteria for rejection.-Findings that 
prompted a work-up and biopsy of the graft in-
cluded fever greater than 38.3 degrees C without 
an identifiable source of infection, diminished 
output of bile or altered character of the bile 
(if a T tube was present), and formation of ascites. 
If total bilirubin, serum glutamic-oxaloacetic trans-
aminase, serum glutamic-pyruvic transaminase, al-
kaline phosphatase or ,),-glutamyl transpeptidase 
measurements were abnormal before the work-up 
to determine rejection, findings greater than 1.5 
times the previous week's value were considered 
suspicious. When the baseline values were nor-
mal, elevations exceeding double the upper limit 
of normal triggered further work-up. 
Histopathologic criteria.-No diagnosis of re-
jection was accepted without verification by bi-
opsy. Findings consistent with acute rejection (14, 
15) were a predominantly mononuclear (50 to 
60 percent) portal tract infiltrate intermixed with 
polymorphonuclear cells and eosinophils, local-
ization of the inflammatory cells around and be-
neath the swollen endothelium of portal capil-
laries and small veins, and/or infiltration and 
damage of the epithelium of small bile ductules. 
The stigmata of chronic rejection were arteriopa-
thy, ductopenia, and fibrosis (14-16). 
Rejection is a diagnosis of exclusion (14-16). 
Therefore, important negative findings were ab-
sence of findings that suggested hepatitis (i.e., 
panlobular inflammations, piecemeal necrosis, 
disarray with ballooning and spotty individual 
hepatocyte necrosis, and prominent lymphohis-
tiocyte infiltration of the hepatic lobule with in-
flammatory cell destruction of hepatocytes), and 
absence of stigmata indicating obstruction of the 
bile duct, including cholangiolar proliferation. 
Details of immunosuppression. Tacrolimus.-The 
starting IV dose of 0.1 mg/kg/day was given by 
constant 24-hour infusion with no IV overlap 
when oral medications were started. A new phy-
sician's order was required each day as long as 
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FIG. 1. The experimental design of the Pittsburgh randomized trial. All treatment 
variables were equal except for the competing drugs (cyclosporine and tacrolimus). 
CyA, Cyclosporine; IV, intravenous; and FK506, tacrolimus. 
the patient was in the hospital. During the period 
of constant IV infusion, dose adjustments were 
considered between normal ordering times if 
changes in the pattern of urine output, evidence 
of neurotoxicity, or other events generated sus-
picion of drug toxicity (7, 8, 17-19). The char-
acteristic side effects of tacrolimus determined 
the maximum dose, and the occurrence of re-
jection established the minimum dose. 
Same-day plasma concentrations of tacrolimus 
(20) were measured in an on-site monoclonal 
immunoassay laboratory (21), which was the only 
one with this capability outside of Japan at the 
time. When the results were correlated with the 
observations about efficacy and toxicity, the ap-
propriate 12-hour plasma trough concentration 
was quickly deduced in the same way that pre-
viously had allowed development of the efficient 
use of cyclosporine with prednisone (22). The 
target 12-hour plasma level of tacrolimus was 1 
to 2 ng/mL, above which the incidence of neph-
rotoxicity, neurotoxicity, and diabetogenicity pro-
gressively rose. 
Trough concentrations greater than 5 ng/mL 
were not permitted. However, when there was 
evidence of rejection, tacrolimus doses were in-
creased to allow trough levels in the 2 to 5 ng/mL 
range, providing this caused little or no toxicity. 
Conversely, doses were reduced if toxicity was 
present, even if trough levels were already low. 
Patients were not discharged from the hospital 
until oral dosages were stable, at which time the 
usual plasma trough levels were near 1 ng/ mL. 
In the months that followed, these plasma con-
centrations and the oral doses were allowed to 
drift down. 
Cyclosporine.-A sliding scale strategy was used 
for dosing, beginning with a 24-hour IV infusion 
of 4 mg/kg/ day and an optional oral starting 
dose of 8 mg/kg cyclosporine every 12 hours. 
In the first month, 12-hour whole blood trough 
concentrations were targeted in the 800 to 1,500 
ng/mL range (23). From the second month on-
ward, those concentrations were permitted to fall 
to 600 to 800 ng/mL or lower if toxicity occurred 
but there was no evidence of rejection. The simi-
larity of side effects between cyclosporine and 
tacrolimus, as well as the fact that doses were 
driven by the same three interrelated factors-
rejection, toxicity, and trough levels-greatly 
facilitated management and outcome compari-
sons between the competing drugs. 
Prednisone.-In the first 81 cases (tacrolimus, 
n=41, cyclosporine, n=40) , methylprednisolone, 
20 mg, was given daily until oral therapy was 
started with prednisone, 20 mg/ day (Fig. 1). A 
dose reduction to 10 mg/ day was allowed on 
both arms of the study at two weeks and a further 
reduction to 5 mg/ day at the end of the month 
if there had been no clinical or histopathologic 
evidence of rejection. Corticosteroids were dis-
continued at the physician's discretion after this 
time. 
Beginning with case 82, methylprednisolone 
(Depo-medrol®, Upjohn, Kalamazoo, MI) 1 g IV, 
was given intraoperatively to both groups. How-
ever, the two arms of the study were unbalanced 
by adding a prophylactic five-day burst of post-
operative methylprednisolone (previously used 
only to treat rejection) beginning on postoper-
ative day one, for subsequent patients randomized 
to receive cyclosporine (n=35), but not to those 
randomized to receive tacrolimus (n=38). The 
additional induction dose for the cyclosporine-
treated patients was a direct response to the high 
H;jection rates observed in that arm of the study. 
Conditions for crossover. Treatment failure was 
defined as the inability of the initial immuno-
suppression therapy plus an orderly sequence of 
secondary therapy (when necessary) to control 
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FIG. 2. Algorithm used to determine treatment failure, with the consequent 
option of crossover to the competing immunosuppressant drug. The diagnosis 
of rejection required proof by biopsy. OKT3, Orthoclone OKT3. 
rejection confirmed by biopsy (Fig. 2). In the 
event of rejection a 1-g bolus of methylpred-
nisolone, which could be repeated once, was 
given. If no response was obtained within 48 
hours, a five-day course of IV OKT3 (10 mL/ day) 
was given. If no improvement or a relapse oc-
curred, a five-day course of tapering corticosteroids 
was given, starting with methylprednisolone, 200 
mg, with 40-mg decrements to a baseline dose 
of 20 mg/ day. If these maneuvers were unsuc-
cessful, crossover from cyclosporine to tacrolimus 
or vice versa was permitted at the discretion of 
the attending surgeons. 
Although crossover to the competing treatment 
was permitted when drug toxicity occurred, the 
TABLE I.-BASELINE CHARACTERISTICS 
Characteristics 
Mean age, y. 
Male sex, percent 
White race, percent 
Blood type, percent 
A 
o 
B 
AB 
Indications for trans-
plant, percent 
Cirrhosis 
Alcoholic. 
Chronic post-NiL"'IB 
Cryptogenic 
Cholestatic disease 
Primary bihary cir-
rhosis 
Sclerosing cholangitis 
Autoimmune hepatitis 
Biliary atresia 
Inborn metabolic dis-
orders 
Other. 
Tacrolimus, 
n=79 
43.2 
62.0 
89.9 
36.7 
43.0 
13.9 
6.3 
35.4 
21.5 
10.1 
10.1 
8.9 
2.5 
2.5 
2.5 
6.3 
CyA, 
n=75 
42.5 
61.3 
88.0 
54.7 
36.0 
5.3 
4.0 
28.0 
18.7 
12.0 
10.7 
8.0 
6.7 
1.3 
,).3 
9.3 
CyA to 
FK, n=47 
42.3 
55.3 
87.2 
48.9 
38.3 
8.5 
4.3 
19.2 
21.3 
12.8 
12.8 
6.4 
8.5 
0.0 
8.5 
10.6 
CyA only, 
n=28 
42.9 
71.4 
89.3 
64.3 
32.1 
0.0 
3.6 
42.9 
14.3 
1(J.7 
7.1 
10.7 
3.6 
3.6 
(J.(J 
7.1 
n, Number of patients; eyA, cyclosporinc; FK, tacrolimus; y, years; and 
",,,"--"lB, non-A, non-B hepatitis. 
side effects never directly necessitated this, be-
cause toxicity could be easily adjusted by increas-
ing or decreasing the doses of drugs adminis-
tered. In the appropriate doses, it was known 
from the preceding pilot experience that the prin-
cipal factors limiting the dosage of tacrolimus 
were the same as for cyclosporine: nephrotoxicity 
(17, 24), diabetogenicity (25), and neurotoxicity 
(24). It also had been established by comparison 
with historical controls that flexible regimens for 
tacrolimus were associated with an equivalent or 
lower rate of infection than those using cyclospor-
ine (7, 8, 26, 27), could be effective with a re-
duced cumulative need for prednisone (7, 8, 28), 
resulted in a lower incidence of hypertension 
(7-9, 17) and hyperlipidemia (7, 8), and did 
not cause the cosmetic changes associated with 
cyclosporine (hirsutism, facial brutalization, and 
gingival hyperplasia) that precluded blinded tri-
als. When used properly, the total treatment regi-
men (especially the prednisone component) re-
quired to control rejection and minimize toxicity 
with either tacrolimus or cyclosporine was never 
identical in any two patients. 
Oversight committee. At the request of the clini-
cians caring for the patients, a multi-institutional 
patients' rights committee (faculty members at 
the University of Pittsburgh, Carnegie Mellon 
University, and Harvard Medical College) was 
convened to evaluate interim results every three 
months and make recommendations to the in-
stitutional review board (IRB) about the con-
tinuation or termination of the trial. 
Statistical analysis. A Cox proportional hazards 
regression model (29) was used to analyze the 
time-to-event data, with treatment effects tested 
for statistical significance using a likelihood ratio 
test. This approach allows for varying lengths of 
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patient follow-up and simultaneous control for 
the effect of patient baseline confounders on 
outcome. The end points for statistical analysis 
were freedom from biopsy-confirmed rejection, 
retransplantation, and death. Crossover was not 
considered to be an end point. 
RESULTS 
Patient characteristics. From February 16, 1990 
to December 26, 1991, 154 patients were re-
cruited, of whom 79 patients were randomized 
to the tacrolimus arm and 75 to the cyclosporine 
arm of the study. The patient groups that 
emerged from the intraoperative randomization 
were similar with respect to baseline charac-
teristics, although there was some imbalance in 
representation by ABO blood type and indications 
for transplant (Table I). All patients were avail-
able for follow-up throughout the trial, which 
terminated on May 30, 1995. The mean duration 
of follow-up was four years. Mter randomization, 
47 patients receiving cyclosporine were crossed 
over to the tacrolimus arm. Of the crossovers, 
70 percent occurred within the first month of 
randomization and another 28 percent during 
the first year of follow-up. Seven patients were 
crossed over before rejection of the transplant, 
whereas the other 40 were switched to tacrolimus 
following rejection (Table II). The remaining 28 
patients randomized to receive cyclosporine re-
mained in the assigned treatment arm for the 
duration of the trial, irrespective of intervening 
episodes of rejection or retransplantation. Only 
one patient in the tacrolimus arm was crossed 
over to cyclosporille. This occurred following re-
transplantation that was preceded by an episode 
of rejection. 
Primary analysis: freedom from rejection. Cox re-
gression analysis was performed using an indi-
cator variable to represent treatment status and 
using time to rejection as the outcome variable. 
The freedom-from-rejection curves (Fig. 3a) 
showed that patients randomized to the tacro-
limus arm were less likely to experience acute 
rejection than were those receiving cyclosporine 
(p=0.003, likelihood ratio test). The freedom 
from rejection at one year was 36.2 percent for 
patients receiving tacrolimus and 16.8 percent 
for patients receiving cyclosporine. Confidence 
limit .. of 95 percent for the 19.4 percentage point 
difference in these rates are 6.9 to 3l.9 percent. 
Note that the interpretation of this intent-to-treat 
analysis is unaffected by the pattern of crossovers, 
as the vast majority (85 percent) of these occurred 
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after rejection (Table II). A subsequent analysis, 
which censored the seven (15 percent) patients 
receiving cyclosporine who were crossed over be-
fore occurrence of an acute rejection, yielded 
similar result.,. An analysis including age, gender, 
TABLE n.-REASONS FOR CROSSOVER FROM CYCLOSPORINE 
TO TACROLIMUS 
Reason faT crossover 
Corticosteroid-resistant rejection 
Refractory rejection .. . 
CyA nephrotoxicity ... . 
Ischemic injury .. 
Hemolysis ........ . 
Family insistence .... . 
Prior to rejection, Following 
n ~ 7 refation, n~4M 
26 
13 
5 
n, Number of patients. and evA, cydosporin. 
._-_._-.---_._--
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TABLE III.-REASONS FOR RETRANSPlANTATION 
Reason 
Rejection ......... . 
Primary failure . . . . . . 
Recurrent liver disease .. 
Vascular event ...... . 
Ischemic injury ..... . 
Infection ......... . 
Tacrolimus, 
n~U 
1 
I 
2 
1 
3 
CyA to FK, 
n~4 
n, Number of patients; CyA, cyclosporin; and FK, tacrolimus. 
CyA only, 
n~U 
4 
4 
race, blood type, indications for transplant, and 
starting dose of prednisone as covariates pro-
duced similar results. 
An assumption underlying the Cox regression 
analysis is that the hazard rates are proportional. 
This assumption was examined by plotting the 
freedom-from-rejection curves on a log-log scale. 
Because the two curves were parallel, the pro-
portional hazards model can be regarded as 
appropriate. 
Exploratory analyses. The unique study design 
and pattern of crossovers influenced the frame-
work for a set of exploratory analyses. For these 
analyses, three groups were compared: the 79 
patients randomized to receive tacrolimus, the 
47 patients who crossed over from cydosporine 
to tacrolimus therapy, and the 28 patients who 
remained in the cydosporine arm of the study. 
The results of these comparisons must be inter-
preted cautiously because they are not protected 
by the randomization process. 
The baseline characteristics for these three 
groups are shown in Table I. Figure 3b shows 
that the freedom-from-rt::.iection curves for pa-
tients who were crossed over from cydosporine 
to tacrolimus therapy are identical to the rejec-
tion curves for those patients who were crossed 
over. This is reassuring, as the vast majority of 
crossovers from cydosporine to tacrolimus ther-
apy occurred after rejection of the transplant. 
There were no statistically significant differences 
among the groups with regard to freedom from 
graft failure (Fig. 4a, p=0.42), defined as a com-
posite outcome of retransplantation or death. 
When these outcomes were considered separately, 
there is a striking difference in freedom from 
retransplantation for patients receiving tacrolimus 
in comparison with those who continued receiv-
ing cydosporine (Fig. 4b, p=0.02). At three years, 
freedom from retransplantation for patients re-
ceiving tacrolimus was 90.3 percent compared 
with 70.7 percent for patients continuing to re-
ceive cydosporine (see reasons for retransplan-
tation in Table III). Finally, survival of patients 
throughout the trial was virtually identical, at 
approximately 84 percent in each of the three 
groups (Fig. 4c, p=0.95). Causes of death are 
listed in Table IV. 
Adverse events. The adverse events encompassed 
complications affecting the central nervous, geni-
tourinary, cardiovascular, respiratory, and gastro-
intestinal systems. Not all adverse events were 
suspected of being side effects of the treatment 
drug. Infections, neoplasms, and hematologic ab-
normalities were treated in the same way. A spec-
trum of complications not obviously related to 
drug therapy induded technical surgical accidents, 
worsening of preexisting cardiovascular disease, 
degenerative disorders, and traumatic accidents. 
Two de novo malignancies developed, one in 
each arm of the study: one patient in the cy-
dosporine group died of a squamous cell car-
cinoma of the larynx after 4.4 years and one 
patient in the tacrolimus group died after 2.3 
years of a disseminated squamous cell carcinoma 
of the oropharynx. Neither patient had been 
crossed over to the other treatment. 
DISCUSSION 
The results of this study indicate that tacrolimus 
is a more potent and satisfactory immunosup-
pressant than is cydosporine for combination 
therapy with prednisone and other adjuvant 
agents. As seen in Figure 3, patients randomized 
to the tacrolimus arm were significantly less likely 
to experience acute rejection than were those 
TABLE IV.-CAUSES OF DEATH 
_Tacrolimus, n~1T_ 
Cause of death 
Infection .................. . 
Vascular event. . . . . . . . . . . . . . . . 
Graft failure . . . . . . . . . . . . . . . . . 
Hepatic disease . . . . . . . . . . . . . . . 
Malignancy. . . . . . . . . . . . . . . . . . 
Multiple organ failure .......... . 
Respiratory failure . . . . . . . . . . . . . 
n 
8 
4 
1 
2 
1 
1 
n, Number of patients; eyA, cyclosporin; and FK, tacrolimus. 
Percent 
47.1 
23.5 
5.9 
11.8 
5.9 
5.9 
n Percent 
5 50.0 
2 20.0 
3 30.0 
n 
2 
I 
I 
Percent 
40.0 
20.0 
20.0 
20.0 
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receIvmg cyclosporine. Survival of patients was 
virtually identical in the two groups. 
Historically, renal transplantation was the whole 
organ procedure with which new immunosup-
pressive drugs and regimens were evaluated (30-
37), and then applied secondarily to the unpaired 
vital organs. This precedent was broken with the 
development of tacrolimus, largely because it was 
demonstrated at the outset that the new agent 
could rescue hepatic grafts from intractable re-
jection under cyclosporine-based immunosup-
pression (4, 5). The consequent demand for 
tacrolimus prompted two decisions by the United 
States Food and Drug Administration (FDA): first, 
to place it on to the developmental "fast track," 
and second, to require two multicenter random-
ized trials. However, randomized rescue trials in 
which half of the patients facing death or re-
transplantation would be assigned to a less potent 
therapeutic option were unappealing. At meet-
ings of the FDA in October and November 1989, 
randomized European and American multicenter 
trials were recommended to compare tacrolimus 
with cyclosporine as the primary immunosuppres-
sant from the time of liver replacement. 
Although this decision averted an indefensible 
rescue trial, it created other issues. By the end 
of 1989, extensive pilot studies already suggested 
that the improvement in outcome, including qual-
ity of life, after transplantation of a variety of 
organs was as obvious as when cyclosporine suc-
ceeded azathioprine (Imuran®, Glaxo Wellcome 
Inc., Research Triangle Park, NC) as the baseline 
immunosuppressant a decade before. On the ear-
lier occasion, recipients of the life-stake organs 
(liver and heart) had been spared randomization. 
All were given cyclosporine, and randomized tri-
als were restricted to renal transplant recipients 
(36) to whom dialysis back-up could be offered. 
In the IRB-mandated Pittsburgh trial compar-
ing tacrolimus with cyclosporine, the resulting 
ethical quandary was dealt with by the experi-
mental design, which had three objectives. The 
first was to identify at an early time those re-
cipients whose liver graft survival would require 
high-dose prednisone therapy or other potentially 
dangerous adjuvant immunosuppression. The sec-
ond objective was to provide a sensitive trigger 
for allowing patients prompt access to the more 
potent baseline drug if they required it. Third, 
scientifically valid safety and efficacy information 
was ensured by equalization at the outset of all 
treatment variables except for the competing 
drugs. After the first 81 cases, the prednisone 
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doses on the cyclosporine arm of the study had 
to be increased because of the high incidence 
of rejection. 
The single-center trial reported here was more 
than half completed before the multicenter trials 
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began in August (12) and September 1990 (11). 
Although the results in all three studies were 
generally congruent, the multicenter protocols 
led to systematic overdosing of tacrolimus. In 
addition, the unequal use of other immunosup-
pressants in the competing arms of the study 
deprived the multicenter investigations of a fo-
cused view of the new drug's potential (37). 
Finally, a handicap in the multicenter trials 
was the unavailability of same-day determinations 
of circulating tacrolimus. Ironically, the results 
of the University of Pittsburgh randomized trial 
were ultimately disqualified for inclusion at the 
FDA advisory hearings because drug monitoring 
had been done by measuring plasma concentra-
tions of tacrolimus, whereas whole blood deter-
mination, which has ten to 20 times higher read-
out, was eventually adopted as the laboratory 
standard. However, both technologies are based 
on the same principle (21), provide results that 
are highly correlated, and have similar accuracy 
(38). Consequently, the plasma method, which 
was the only one available at the beginning of 
1990 (and only in Japan and in the Pittsburgh 
laboratories), provided on-site pharmacokinetic 
data (7, 8, 17, 19, 20, 24) that remain useful 
and valid today. 
Although the Pittsburgh trial was smaller than 
the multicenter trials referred to here, it was 
characterized by a substantially longer follow-up 
period, and therefore adds further understanding 
to the relative properties of immunosuppressant 
agents. The same general conclusions as those 
from the hepatic transplantation trials have been 
reported to apply for renal (39), pulmonary (40), 
and cardiac (41) transplantation. 
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